Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2024-04-30 | OncoZenge | Kallelse till årsstämma i OncoZenge AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-26 | OncoZenge | OncoZenge AB: OncoZenge Appoints Anna Asplind as Phase 3 Program Manager | Pressreleaser | Visa Stäng |
|
||||
2024-04-26 | OncoZenge | OncoZenge AB: OncoZenge anlitar Anna Asplind som Fas 3 Programledare | Pressreleaser | Visa Stäng |
|
||||
2024-04-26 | OncoZenge | OncoZenge AB publicerar årsredovisning för 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-04-25 | OncoZenge | OncoZenge AB: OncoZenge publicerar rapport om BupiZenge™ och otillfredsställda medicinska behov | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-25 | OncoZenge | OncoZenge AB: OncoZenge Releases Paper on BupiZenge™ Addressing Unmet Medical Needs | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-09 | OncoZenge | OncoZenge AB: OncoZenge anlitar Åsa Nilsson som klinisk prövningsledare | Pressreleaser | Visa Stäng |
|
||||
2024-04-09 | OncoZenge | OncoZenge AB: OncoZenge Appoints Åsa Nilsson as Clinical Research Manager | Pressreleaser | Visa Stäng |
|
||||
2024-04-08 | OncoZenge | OncoZenge AB: OncoZenge Announces Dr. Paolo Bossi as New Member of the Advisory Board | Pressreleaser | Visa Stäng |
Pressreleaser |
OncoZenge AB: OncoZenge Announces Dr. Paolo Bossi as New Member of the Advisory BoardThe OncoZenge Advisory Board was established in December 2023 with the objective of supporting the company in its efforts to lead BupiZenge™ through clinical development, market introduction and commercialization, with Dr Stephen Sonis and Dr Pooja Nandwani Patel as founding members. The company is pleased to now welcome Dr Paolo Bossi, Medical Oncologist and Associate Professor of Medical Oncology and Head of the Head and Neck Cancer Unit at the Humanitas University in Milan, Italy, to the Advisory Board. ”We are honored Dr Paolo Bossi, a highly accomplished medical oncologist with long experience from medical research in both cancer and cancer supportive care, has offered his support to our team and company on the mission to bring our drug candidate to the patients who need it”, says Stian Kildal, CEO of OncoZenge. ”Dr Bossi’s insights will prove invaluable as he brings an important European perspective ahead of our Phase 3 clinical trial for Europe currently in planning. In addition, Dr Bossi’s deep experience as Chair of the Mucositis study group at MASCC (Multinational Association of Supportive Care in Cancer) will be instrumental both for our near-term activities to progress BupiZenge towards market approval, as well as for the development of new pipeline candidates.” Dr Paolo Bossi commented, ”I have followed OncoZenge for some time and recognize a clear need for a more effective, non-opioid pain management solution for the many cancer patients who suffer from oral pain during their radiation and chemotherapies. Today’s standard of care severely impacts not only patients’ quality of life, but also their prognosis due to non-adherence to treatment, weight loss and prolonged recovery times due to the oral pain and difficulty of maintaining proper nutrition. I look forward to supporting OncoZenge on their mission to bring their innovation to patients.” About Dr Paolo Bossi Paolo Bossi is a Medical Oncologist, Associate Professor and Head of the Head and Neck Cancer Unit at the Humanitas University and Humanitas Cancer Center in Milan, Italy. He is involved in all institutional research activities on head and neck cancer, from translational research (gene expression, next generation sequencing) to assessment of quality of life and value-based medicine. He is particularly dedicated to rare cancer among head and neck cancers (paranasal sinus cancer, adnexal cancer, nasopharyngeal cancer, salivary gland cancer). He has strong experience with medical treatment of non-melanoma skin cancer, designing and conducting trials with targeted therapy and immunotherapy. He has a strong commitment to supportive care, specifically for what concerns mucositis induced by cancer therapies. He collaborates with the Italian Network on Rare Tumors, a collaborative effort among Italian cancer centers, which tries to exploit distant patient sharing to improve quality of care and diminish health migration for rare solid cancers. He is the Principal Investigator and co-investigator of several Italian and International trials on Head and Neck cancer and non-melanoma skin cancer. Current responsibilities include; ESMO – Member of ESMO head and neck group and supportive and palliative care group For additional information, please contact: Certified Adviser OncoZenge AB About OncoZenge OncoZenge has its headquarters in Stockholm, Sweden, and its share is publicly traded on Nasdaq First North Growth Market under the ticker ONCOZ. |
||||
2024-04-05 | Impala Nordic | Impala Nordic: OncoZenge - Positiva stabilitetsdata för BupiZenge™ och prospektering av samarbeten i Kina | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-04 | OncoZenge | OncoZenge AB: OncoZenge erhåller positiva stabilitetsdata för BupiZenge™ | Pressreleaser | Visa Stäng |
|
||||
2024-04-04 | OncoZenge | OncoZenge AB: OncoZenge Announces Read-out of Positive Stability Data for BupiZenge™ | Pressreleaser | Visa Stäng |
|
||||
2024-03-20 | OncoZenge | OncoZenge AB byter Certified Adviser till Redeye AB | Pressreleaser | Visa Stäng |
|
||||
2024-03-11 | OncoZenge | OncoZenge AB: OncoZenge utforskar strategiska alternativ för BupiZenge™ i Kina | Pressreleaser | Visa Stäng |
|
||||
2024-03-11 | OncoZenge | OncoZenge AB: OncoZenge Explores Strategic Options for BupiZenge™ in China | Pressreleaser | Visa Stäng |
|
||||
2024-02-28 | Impala Nordic | Impala Nordic: OncoZenge - Rapportkommentar och PRIME besked | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-22 | Penser Access by Carnegie | Penser Access by Carnegie: Intervju med OncoZenge - Carnegie Investment Bank - 22 feb 2024 | Pressreleaser | Visa Stäng |
|
||||
2024-02-21 | Impala Nordic | Impala Nordic: OncoZenge - Poddintervju med VD, Stian Kildal och storägare Niclas Holmgren | Pressreleaser | Visa Stäng |
|
||||
2024-02-20 | Penser Access by Carnegie | Penser Access by Carnegie: OncoZenge - På rätt spår, söker kommersiellt avtal | Pressreleaser | Visa Stäng |
|
||||
2024-02-15 | OncoZenge | OncoZenge AB bokslutskommuniké 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-07 | OncoZenge | OncoZenge AB: OncoZenge lämnar in patentansökan för stärkt IP skydd för BupiZenge™ | Pressreleaser | Visa Stäng |
|
||||
2024-02-07 | OncoZenge | OncoZenge AB: OncoZenge Files Patent Application for Strengthened IP Protection for BupiZenge™ | Pressreleaser | Visa Stäng |
|
||||
2024-01-16 | Impala Nordic | Impala Nordic: OncoZenge: Analys - Sikte på partnerskap och Fas-3 studier | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-03 | Impala Nordic | Impala Nordic: OncoZenge - Intervju med VD, Stian Kildal: "Fokus är att säkra ett strategiskt samarbetsavtal för exekvering av fas 3 programmet" | Pressreleaser | Visa Stäng |
|
||||
2024-01-02 | OncoZenge | OncoZenge AB: OncoZenge lämnar in ansökan om PRIME-status i EU | Pressreleaser | Visa Stäng |
|
||||
2024-01-02 | OncoZenge | OncoZenge AB: OncoZenge submits application for PRIME status in the EU | Pressreleaser | Visa Stäng |
|
||||
2023-12-13 | OncoZenge | OncoZenge AB: OncoZenge Announces Advisory Board with Dr Stephen Sonis and Dr Pooja Nandwani Patel | Pressreleaser | Visa Stäng |
|
||||
2023-11-30 | OncoZenge | OncoZenge AB: OncoZenge byter Certified Adviser till Carnegie Investment Bank AB (publ) | Pressreleaser | Visa Stäng |
|
||||
2023-11-28 | OncoZenge | OncoZenge AB: Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge™ in the United States | Pressreleaser | Visa Stäng |
|
||||
2023-11-28 | OncoZenge | OncoZenge AB: OncoZenge - VD kommentar till avsiktsförklaring med Ensysce Biosciences, Inc | Pressreleaser | Visa Stäng |
|
||||
2023-11-24 | OncoZenge | OncoZenge AB: OncoZenge tillhandahåller strategiuppdatering | Pressreleaser | Visa Stäng |
|
||||
2023-11-24 | OncoZenge | OncoZenge AB: OncoZenge provides strategy update | Pressreleaser | Visa Stäng |
|
||||
2023-11-21 | OncoZenge | OncoZenge AB: OncoZenge - Den nya formuleringen av BupiZenge™ är ren | Pressreleaser | Visa Stäng |
|
||||
2023-11-21 | OncoZenge | OncoZenge AB: The new formulation of OncoZenge's drug candidate BupiZenge™ is clean | Pressreleaser | Visa Stäng |
|
||||
2023-11-14 | Penser Access | Penser Access: Intervju med OncoZenge - Erik Penser Bank - 14 november 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-11-08 | Penser Access | Penser Access: BupiZenge i fokus - OncoZenge | Pressreleaser | Visa Stäng |
|
||||
2023-11-02 | OncoZenge | OncoZenge AB (publ) styrelse fulltecknade i bolagets optionsprogram | Pressreleaser | Visa Stäng |
|
||||
2023-11-01 | OncoZenge | OncoZenge AB (publ) VD Stian Kildal fulltecknade 500,000 teckningsoptioner i bolagets optionsprogram | Pressreleaser | Visa Stäng |
|
||||
2023-11-01 | OncoZenge | OncoZenge AB: Kommuniké från OncoZenges extra bolagsstämma den 1 november 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-10-31 | OncoZenge | OncoZenge AB (publ) publicerar delårsrapport för perioden 1 januari 2023 - 30 september 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-10-17 | OncoZenge | OncoZenge AB: ONCOZENGES VALBEREDNING UTSEDD | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-16 | OncoZenge | Kallelse till extra bolagsstämma i OncoZenge AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-09 | OncoZenge | OncoZenge AB: OncoZenge tillsätter Michael Owens som ny CFO | Pressreleaser | Visa Stäng |
|
||||
2023-10-06 | OncoZenge | OncoZenge AB: OncoZenge tidigarelägger publicering av delårsrapport för januari-september 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-09-21 | OncoZenge | OncoZenge AB: VD köper aktier i OncoZenge | Pressreleaser | Visa Stäng |
|
||||
2023-09-12 | Penser Access | Penser Access: Samma bolag, nya människor - OncoZenge | Pressreleaser | Visa Stäng |
|
||||
2023-09-11 | OncoZenge | OncoZenge AB utser ny VD | Pressreleaser | Visa Stäng |
|
||||
2023-09-09 | OncoZenge | OncoZenge AB: Styrelsen i OncoZenge beslutar om reviderad strategi. | Pressreleaser | Visa Stäng |
|
||||
2023-09-08 | OncoZenge | OncoZenge AB: Kommuniké från OncoZenges extra bolagsstämma den 8 september 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-08-31 | OncoZenge | OncoZenge AB: Delårsrapport Jan-Jun 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-28 | OncoZenge | OncoZenge AB: Aktieägaren Niclas Holmgrens förslag inför extra bolagsstämman den 8 september 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-08-25 | OncoZenge | OncoZenge AB: Öppetbrev från Styrelseledamot Niclas Holmgren | Pressreleaser | Visa Stäng |
|
||||
2023-08-22 | OncoZenge | Kallelse till extra bolagsstämma i OncoZenge AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-21 | OncoZenge | OncoZenge AB: OncoZenge senarelägger delårsrapport för det andra kvartalet 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-21 | OncoZenge | OncoZenge AB: Tre styrelseledamöter och verkställande direktören i OncoZenge avgår | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-21 | OncoZenge | OncoZenge AB: Kommuniké från OncoZenges extra bolagsstämma den 21 augusti 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-03 | Penser Access | Penser Access: Pausar utvecklingen av BupiZenge - OncoZenge | Pressreleaser | Visa Stäng |
|
||||
2023-08-02 | OncoZenge | OncoZenge AB: OncoZenge pausar utvecklingen av BupiZenge® | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-01 | OncoZenge | Kallelse till extra bolagsstämma i OncoZenge AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-16 | OncoZenge | OncoZenge AB: Försening i utvecklingsarbetet för BupiZenge® | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-31 | OncoZenge | OncoZenge AB: Kommuniké från OncoZenges årsstämma den 31 maj 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-17 | Penser Access | Penser Access: Förbereder för PK-studie - OncoZenge | Pressreleaser | Visa Stäng |
|
||||
2023-05-16 | Penser Access | Penser Access: Intervju med OncoZenge - Erik Penser Bank - 16 maj 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-05-16 | OncoZenge | OncoZenge AB delårsrapport jan - mar 2023 | Rapporter | Ladda ner | Visa Stäng |
|